Patient P-01394

Synthetic patientNBL-101 · Day 108 · 45–54 · M · baseline S05Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

53%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S05
Day 41 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 SC-12 recommended — Supportive Compound SC-12
Day 53 Patient accepted — Started SC-12 in the companion
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 59 GI symptom burden −19% vs expected — Supportive Compound SC-12
Day 63 No meaningful change — GI Support Protocol GI-04
Day 65 Tolerance state changed — Unstable → Improving
Day 71 ME-01 recommended — Monitoring Escalation ME-01
Day 72 Patient accepted — Started ME-01 in the companion
Day 75 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 41.

Primary contributors, last 14 days

Toxicity-14
Inflammatory activity-7
Treatment adherence+5
GI instability-2
Nutritional resilience-2

What helped?

Supportive Compound SC-12Day 52
Result: symptom burden −19%
GI Support Protocol GI-04Day 54
Result: no meaningful change
Monitoring Escalation ME-01Day 71
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

49%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

50.1/100

improving · -13.4 vs previous 14 d

Toxicity

Blood

40.9/100

improving · -2.8 vs previous 14 d

Sleep quality

Wearable

30.8/100

improving · +5.3 vs previous 14 d

Energy level

Daily log

3.2/10

improving · +0.7 vs previous 14 d

Stress level

Daily log

5.7/10

improving · -0.8 vs previous 14 d

Steps

Wearable

4,432

improving · +559 vs previous 14 d

Adherence

Companion

50.5 %

stable · +0.4 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 33 from the failing basin, 54 from restoration.

Good elements to keep

Supportive Compound SC-12
intervention · steering +31
Monitoring Escalation ME-01
intervention · steering +4
Daily walks resumed
perturbation · steering +3.3

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Dietary fat load
perturbation · steering -11.7
FUT2 non-secretor
hidden · steering -10.6
Histamine load
perturbation · steering -10.5
Dietary fat load
detractor · GI +6.4 next day
Histamine load
detractor · GI +5.9 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+6.4detractor · 95%
Histamine load
+5.9detractor · 95%
Simple carbohydrates
+4.7detractor · 95%
Alcohol
+4.7detractor · 95%
Spicy / capsaicin
+3.7detractor · 95%
Insoluble fibre
-0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- WearableSleep 5.7 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 50
Autonomic recovery ↓45
- WearableResting HR 79 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 41

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 26/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 43 ms
Sleep: 5.6 h
Steps: 4,595
Resting HR: 76 bpm

Daily log: GI score 50, nutritional resilience 43, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01834	53%	S14	NP-02	improved	44
P-01782	50%	S14	NP-02	no change	48
P-01494	49%	S14	GI-04	improved	42
P-01559	49%	S06	GI-04	improved	42
P-01365	48%	S14	SC-12	improved	49
P-01389	48%	S14	SC-12	improved	46
P-01413	48%	S14	GI-04	improved	44
P-01486	48%	S18	GI-04	improved	47
P-01564	47%	S14	ME-01	improved	39
P-01777	47%	S14	SC-12	improved	43
P-01327	46%	S01	GI-04	improved	56
P-01429	46%	S09	GI-04	improved	45